Takotsubo Cardiomyopathy During Anti-HER2 Therapy for Metastatic Breast Cancer |
| |
Authors: | Caitlin Lees Payam Yazdan-Ashoori Katarzyna J. Jerzak Sonal Gandhi |
| |
Affiliation: | 1. Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada;2. Department of Medicine, University of Toronto, Toronto, Ontario, Canada;3. Department of Medicine, University of Toronto, Toronto, Ontario, Canada Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada |
| |
Abstract: | Human epidermal growth factor receptor 2 (HER2)-targeted antibodies, including pertuzumab and trastuzumab, improve overall survival and progression-free survival among women with HER2-positive metastatic breast cancer, but grade ≥3 cardiotoxicity occurs in approximately 8% of cases. Here we report a case of Takotsubo cardiomyopathy associated with the use of dual anti-HER2 therapy in a 63-year-old woman who presented to the emergency department with an 8- to 10-hour history of progressive dyspnea after completing her third cycle of pertuzumab plus trastuzumab in addition to nab-paclitaxel chemotherapy. To our knowledge, this patient represents the first reported case of Takotsubo cardiomyopathy associated with pertuzumab plus trastuzumab combination therapy in the literature. |
| |
Keywords: | |
|
|